{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:37:03Z","timestamp":1789522623029,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K11139"],"award-info":[{"award-number":["16K11139"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K11278"],"award-info":[{"award-number":["17K11278"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ajog.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T21:50:09Z","timestamp":1597787409000},"page":"197.e1-197.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma"],"prefix":"10.1016","volume":"224","author":[{"given":"Ruriko","family":"Nakae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-9994","authenticated-orcid":false,"given":"Shinya","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Serada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Okazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Egawa-Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.08.028_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","article-title":"Soft tissue and uterine leiomyosarcoma","volume":"36","author":"George","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2020.08.028_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2020.08.028_bib3","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib4","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.ajog.2019.07.030","article-title":"Copper ions are novel therapeutic agents for uterine leiomyosarcoma","volume":"222","author":"Kakuda","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.08.028_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728222.2014.882323","article-title":"Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers","volume":"18","author":"Matsuzaki","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ajog.2020.08.028_bib6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.1991.9.11.1962","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study","volume":"9","author":"Thigpen","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2020.08.028_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/14656566.2019.1571042","article-title":"Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas","volume":"20","author":"Tantari","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajog.2020.08.028_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2017.06.018","article-title":"Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial","volume":"146","author":"Hensley","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2020.08.028_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2020.08.028_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2020.08.028_bib11","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0092-8674(93)90133-B","article-title":"Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor","volume":"73","author":"Goodwin","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ajog.2020.08.028_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/intimm\/6.3.477","article-title":"CD70 represents the human ligand for CD27","volume":"6","author":"Hintzen","year":"1994","journal-title":"Int Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/14728222.12.3.341","article-title":"CD70 as a therapeutic target in human malignancies","volume":"12","author":"Grewal","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ajog.2020.08.028_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0167-5699(94)90077-9","article-title":"CD27: marker and mediator of T-cell activation?","volume":"15","author":"Hintzen","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.ajog.2020.08.028_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/smim.1998.0154","article-title":"Control of lymphocyte function through CD27-CD70 interactions","volume":"10","author":"Lens","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.coi.2005.04.004","article-title":"CD27 and CD70 in T cell and B cell activation","volume":"17","author":"Borst","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib18","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2020.08.028_bib19","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood.V85.12.3556.bloodjournal85123556","article-title":"Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells","volume":"85","author":"Ranheim","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2020.08.028_bib20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.exphem.2005.10.005","article-title":"Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL","volume":"33","author":"Nilsson","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ajog.2020.08.028_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ni869","article-title":"Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions","volume":"4","author":"Tesselaar","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib23","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.4049\/jimmunol.172.12.7432","article-title":"CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation","volume":"172","author":"Xiao","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ajog.2020.08.028_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-14-1425","article-title":"pVHL\/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma","volume":"21","author":"Ruf","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14728222.2016.1158812","article-title":"Therapeutic targeting of CD70 and CD27","volume":"20","author":"Wajant","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ajog.2020.08.028_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2020.08.028_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ajog.2020.08.028_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ajog.2020.08.028_bib29","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ijc.28526","article-title":"Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A","volume":"134","author":"Matsuzaki","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ijc.31124","article-title":"Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer","volume":"142","author":"Matsuzaki","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.27679","article-title":"Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer","volume":"132","author":"Yokoyama","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib32","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/0008-5472.CAN-17-0910","article-title":"LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake","volume":"78","author":"Hiramatsu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib33","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.18632\/oncotarget.2306","article-title":"Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner","volume":"5","author":"Morimoto","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajog.2020.08.028_bib34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.3363","article-title":"In\u00a0vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy","volume":"12","author":"Chittajallu","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.ajog.2020.08.028_bib36","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1038\/ncomms7520","article-title":"Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA","volume":"6","author":"L\u00e9veill\u00e9","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2020.08.028_bib37","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ajpath.2019.12.008","article-title":"A\u00a0role of the heme degradation pathway in shaping prostate inflammatory responses and lipid metabolism","volume":"190","author":"Lilljebj\u00f6rn","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajog.2020.08.028_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.bjc.6605816","article-title":"Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75","volume":"103","author":"Ryan","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib39","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajog.2020.08.028_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A\u00a0phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ajog.2020.08.028_bib42","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib43","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","article-title":"Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker","volume":"14","author":"Oflazoglu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib44","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/2159-8290.CD-NB2017-132","article-title":"Gemtuzumab ozogamicin makes a comeback","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajog.2020.08.028_bib45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajog.2020.08.028_bib46","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-05-2883","article-title":"Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates","volume":"66","author":"Law","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib47","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clml.2018.05.006","article-title":"Investigational antibody-drug conjugates for treatment of B-lineage malignancies","volume":"18","author":"Herrera","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ajog.2020.08.028_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ajog.2020.08.028_bib49","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.immuni.2012.09.009","article-title":"The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity","volume":"38","author":"Coquet","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ajog.2020.08.028_bib51","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib52","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib53","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.ajog.2019.07.030","article-title":"Copper ions are novel therapeutic agents for uterine leiomyosarcoma","volume":"222","author":"Kakuda","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.08.028_bib54","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ijc.28526","article-title":"Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A","volume":"134","author":"Matsuzaki","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ijc.31124","article-title":"Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer","volume":"142","author":"Matsuzaki","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.27679","article-title":"Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer","volume":"132","author":"Yokoyama","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/0008-5472.CAN-17-0910","article-title":"LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake","volume":"78","author":"Hiramatsu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2020.08.028_bib58","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajog.2020.08.028_bib59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2020.08.028_bib60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.3363","article-title":"In\u00a0vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy","volume":"12","author":"Chittajallu","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.ajog.2020.08.028_bib61","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1038\/ncomms7520","article-title":"Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA","volume":"6","author":"L\u00e9veill\u00e9","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2020.08.028_bib62","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ajpath.2019.12.008","article-title":"A\u00a0role of the heme degradation pathway in shaping prostate inflammatory responses and lipid metabolism","volume":"190","author":"Lilljebj\u00f6rn","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajog.2020.08.028_bib63","doi-asserted-by":"crossref","first-page":"e001071","DOI":"10.1136\/bmjopen-2012-001071","article-title":"Level of phosphohistone H3 among various types of human cancers","volume":"2","author":"Sun","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajog.2020.08.028_bib64","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.18632\/oncotarget.2306","article-title":"Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner","volume":"5","author":"Morimoto","year":"2014","journal-title":"Oncotarget"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820308565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820308565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:31:04Z","timestamp":1757590264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820308565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0002937820308565"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.08.028","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}